The difference in SBP and DBP between ACE inhibitor users and NoBPMed was significantly greater in those with obesity compared to normal weight (SBP: −15 ± 1 mmHg versus −7 ± 1 mmHg, P=0.002; DBP: −7 ±1 mmHg versus −2 ± 1 mmHg, P=0.002). Here, ACE is linked to obesity due to melanocortin 4 receptor deficiency.